...
首页> 外文期刊>Plant Biotechnology Journal >Characterization and downstream mannose phosphorylation of human recombinant ???±?¢????L?¢????iduronidase produced in Arabidopsis complex glycan?¢????deficient ( cgl ) seeds
【24h】

Characterization and downstream mannose phosphorylation of human recombinant ???±?¢????L?¢????iduronidase produced in Arabidopsis complex glycan?¢????deficient ( cgl ) seeds

机译:拟南芥复合聚糖缺陷型(cgl)种子中产生的人重组α-β-内酰胺酶的特征和下游甘露糖磷酸化

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Summary Mucopolysaccharidosis (MPS) I is a lysosomal storage disease caused by a deficiency of ???±?¢????L?¢????iduronidase (IDUA) (EC 3.2.1.76); enzyme replacement therapy is the conventional treatment for this genetic disease. Arabidopsis cgl mutants are characterized by a deficiency of the activity of N ?¢????acetylglucosaminyl transferase I (EC 2.4.1.101), the first enzyme in the pathway of hybrid and complex N ?¢????glycan biosynthesis. To develop a seed?¢????based platform for the production of recombinant IDUA for potential treatment of MPS I, cgl mutant seeds were generated to express human IDUA at high yields and to avoid maturation of the N ?¢????linked glycans on the recombinant human enzyme. Enzyme kinetic data showed that cgl ?¢????IDUA has similar enzymatic properties to the commercial recombinant IDUA derived from cultured Chinese hamster ovary (CHO) cells (Aldurazyme TM ). The N ?¢????glycan profile showed that cgl ?¢????derived IDUA contained predominantly high?¢????mannose?¢????type N ?¢????glycans (94.5%), and the residual complex/hybrid N ?¢????glycan?¢????containing enzyme was efficiently removed by an additional affinity chromatography step. Furthermore, purified cgl ?¢????IDUA was amenable to sequential in vitro processing by soluble recombinant forms of the two enzymes that mediate the addition of the mannose?¢????6?¢????phosphate (M6P) tag in mammalian cells?¢????UDP?¢????GlcNAc:lysosomal enzyme N ?¢????acetylglucosamine (GlcNAc)?¢????1?¢????phosphotransferase?¢????and GlcNAc?¢????1?¢????phosphodiester ???±?¢???? N ?¢????acetylglucosaminidase (the ?¢????uncovering enzyme?¢????). Arabidopsis seeds provide an alternative system for producing recombinant lysosomal enzymes for enzyme replacement therapy; the purified enzymes can be subjected to downstream processing to create the M6P, a recognition marker essential for efficient receptor?¢????mediated uptake into lysosomes of human cells.
机译:概述粘多糖贮积病(MPS)I是一种溶酶体贮积病,由缺乏β-葡糖醛酸苷(IDUA)(EC 3.2.1.76)引起。酶替代疗法是该遗传疾病的常规疗法。拟南芥cgl突变体的特征在于缺乏Nα-β-乙酰氨基葡糖基转移酶I(EC 2.4.1.101)的活性,该酶是杂化和复合Nα-β-聚糖的生物合成途径中的第一个酶。为了开发用于生产可能用于治疗MPS I的重组IDUA的基于种子的平台,产生了cgl突变体种子以高产量表达人IDUA并避免了Nα成熟。重组人酶上连接的聚糖。酶动力学数据表明,cglΔIDΔIDUA具有与衍生自培养的中国仓鼠卵巢(CHO)细胞(Aldurazyme TM)的商业重组IDUA相似的酶特性。 Nα-β-聚糖谱显示,衍生自cglα-β-淀粉的IDUA主要含有高α-β-甘露糖-β-甘露糖类型的Nα-β-β-聚糖(94.5%)。 ,并通过额外的亲和层析步骤有效地除去了残留的含复合物/杂合的N 3 -C 10聚糖的酶。此外,纯化的cglΔβΔIDUA适合于通过介导添加甘露糖β-β-6β-β-磷酸(M6P)的两种酶的可溶性重组形式进行的体外连续加工。标记在哺乳动物细胞中:UDP:GlcNAc:溶酶体酶N:乙酰基葡萄糖胺(GlcNAc):1:磷酸转移酶。和GlcNAc?1?1 ????磷酸二酯? N-----乙酰氨基葡糖苷酶(该---覆盖酶)。拟南芥种子为生产用于酶替代疗法的重组溶酶体酶提供了另一种系统。纯化的酶可以进行下游加工以产生M6P,M6P是有效的受体介导的人体细胞溶酶体摄取必需的识别标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号